tiprankstipranks
Trending News
More News >

UBS Reduces Stake in Mayne Pharma Group

Story Highlights
UBS Reduces Stake in Mayne Pharma Group

Confident Investing Starts Here:

Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.

UBS Group AG and its related bodies have reduced their voting power in Mayne Pharma Group Limited from 8.79% to 7.26%, reflecting a change in their substantial holding. This adjustment in UBS’s stake could influence the company’s shareholder dynamics and potentially impact its strategic decisions, as substantial holders often play a significant role in corporate governance.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceutical products. The company is known for its commitment to providing quality medications and has a market presence in various regions, catering to diverse healthcare needs.

Average Trading Volume: 929,190

Technical Sentiment Signal: Buy

Current Market Cap: A$526.5M

For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1